CA-SCIENTIST.COM
2.12.2020 10:35:04 CET | Business Wire | Press release
Scientist.com, the healthcare industry’s leading marketplace for outsourced research, has partnered with Enhancing Quality In Preclinical Data (EQIPD) to help define and improve data quality within preclinical research. A self-certification questionnaire is now accessible via Scientist.com’s award-winning compliance solution COMPLi®, allowing global suppliers to self-certify prior to working with biopharma research organizations. With this self-certification, suppliers demonstrate their data integrity processes and procedures to potential clients.
“EQIPD’s holistic approach to tackling the challenges related to data quality within preclinical research aligns with our COMPLi standards, which provides researchers with the proper due diligence necessary to source from suppliers of preclinical services,” stated Matt McLoughlin, VP of Categories & Compliance. “We are working with EQIPD to ensure data integrity is at the heart of research.”
Currently, there are no globally accepted quality standards when it comes to reporting data generated by preclinical research. To define and implement such standards EQIPD has formed a consortium of key stakeholders that includes large pharma (including a number of current Scientist.com clients), biotech companies, academia and compliance solutions. The consortium works closely with Stakeholder Group members such as Scientist.com. EQIPD is looking to develop best practices that can be shared across R&D in the life sciences.
“Use of the EQIPD-derived tools by stakeholders such as Scientist.com enables EQIPD to deliver its mission of improving data integrity standards across the global research community,” stated Anton Bespalov of PAASP, an EQIPD consortium member. “Their COMPLi platform can increase visibility to our work and ensure it aligns completely with the goals of EQIPD moving forward.”
“Including a self-certification questionnaire, based on the EQIPD standard, within COMPLi, streamlines and harmonises the data quality and data integrity due diligence process applied by biopharma research organizations during the on-boarding of preclinical service suppliers,” stated Sandrine Bongiovanni of Novartis Pharma AG.
Research organizations looking to self-certify or learn more about COMPLi can visit https://www.scientist.com/compli/
About Scientist.com
Scientist.com is the pharmaceutical industry’s leading AI-powered marketplace for outsourced R&D. The marketplace simplifies R&D sourcing, saves time and money, reduces risk, and provides access to the latest innovative tools and technologies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, over 80 biotechnology companies, the Biotechnology Innovation Organization (BIO), and the US National Institutes of Health (NIH).
Join Scientist.com on social media: LinkedIn , Twitter , YouTube , Facebook , and Instagram
About EQIPD
The Enhancing Quality in Preclinical Data consortium (EQIPD; previously "European Quality in Preclinical Data") was founded in 2017 by 29 academic institutions, pharmaceutical companies, and SMEs from 8 countries (https://quality-preclinical-data.eu ).
Supported through the European Union’s Innovative Medicines Initiative (IMI), major deliverables of the EQIPD consortium were the development of a novel preclinical research quality system that could be applied in both the public and private sectors, and the generation of online training capacity in good research practice.
The consortium works closely with a large group of associated collaborators, advisors and stakeholders drawn from nearly 100 organizations in Europe and the US and including research institutions, publishers, funders, learned societies and professional societies.
Follow EQIPD on social media:
https://www.facebook.com/EQIPD/
https://twitter.com/EQIPD
https://www.linkedin.com/groups/12074241/profile
View source version on businesswire.com: https://www.businesswire.com/news/home/20201201005416/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom